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Abstract
Background:  The serum response element (SRE) in the c-fos promoter is a convergence point
for several signaling pathways that regulate induction of the c-fos gene. Many transcription factors
regulate the  SRE,  including  serum response  factor  (SRF),  ternary  complex  factor (TCF), and
CCAAT/enhancer binding protein-beta (C/EBPβ ). Independently, the TCFs and C/EBPβ  have been
shown to interact with SRF and to respond to Ras-dependent signaling pathways that result in
transactivation of the SRE. Due to these common observations, we addressed the possibility that
C/EBPβ  and Elk-1 could both be necessary for Ras-stimulated transactivation of the SRE.
Results:   I n  t h i s  r e p o r t ,  w e  d e m o n s t r a t e  t h a t  E l k - 1  a n d  C / E B P β   functionally  synergize  in
transactivation of both a Gal4 reporter plasmid in concert with Gal4-SRF and in transactivation of
the SRE. Interestingly, this synergy is only observed upon activation of Ras-dependent signaling
pathways. Furthermore, we show that Elk-1 and C/EBPβ  could interact both in an in vitro GST-
pulldown assay and in an in vivo co-immunoprecipitation assay. The in vivo interaction between the
two proteins is dependent on the presence of activated Ras. We have also shown that the C-
terminal domain of C/EBPβ  and the N-terminal domain of Elk-1 are necessary for the proteins to
interact.
Conclusions:  These data show that C/EBPβ  and Elk-1 synergize in SRF dependent transcription
of both a Gal-4 reporter and the SRE. This suggests that SRF, TCF, and C/EBPβ  are all necessary
for maximal induction of the c-fos SRE in response to mitogenic signaling by Ras.
Introduction
c-fos is a member of the family of immediate early genes,
and its transcription is transiently induced in response to
mitogenic signals [1]. The serum response element
(SRE) is located approximately 300 bp upstream of the
transcriptional start site in the c-fos promoter and is nec-
essary for serum induction of c-fos [2]. The SRE binds a
transcription factor named serum response factor (SRF)
which was found to be necessary, but not sufficient, for
serum induction of the SRE [3,4,5]. In vivo footprinting
analysis shows that SRF is constitutively bound to the
SRE in both quiescent and growth factor stimulated cells
[6]. This suggests that it is the transcriptional activation
of a complex of SRF and its accessory proteins that is reg-
ulated rather than regulation of SRF DNA binding.
The ternary complex factors (TCFs) are members of the
ets family of transcription factors. The TCF family mem-
bers Elk-1 [7], SAP-1 [8], and SAP-2/ERP/NET [9, 10]
have been found to have a role in regulating the SRE.
TCFs cannot bind the SRE autonomously, but require
protein-protein interactions with SRF in order to bind
the SRE [11,12,13,14,15]. The TCFs contain 3 conserved
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motifs termed the A, B, and C boxes [16]. The N-terminal
A-box (amino acids (aa) 1-90 of Elk-1) is necessary to
bind DNA, while the central B-box (aa 148-168) is the
SRF interaction domain. The C-terminal C-box (aa 352-
399), harboring the transactivation domain, contains
several consensus mitogen activated protein kinase
(MAPK) phosphorylation sites. Accordingly, the TCFs
have been found to be targets of the Ras-Raf-MAPK sig-
nal transduction pathway [16]. In addition, the TCFs
have been found to be targets for all three families of
MAPKs: the extracellular signal-regulated kinases 1/2
(ERK1/2), the jun-N-terminal kinases/stress activated
protein kinases (JNK/SAPK), and the p38 kinase [17,
18]. The transcriptional activity of the TCFs are stimulat-
ed by phosphorylation of the C-terminal MAPK sites [16,
17].
Another transcription factor that is involved in regula-
tion of the c-fos SRE is CCAAT/Enhancer binding pro-
tein-beta (C/EBPβ ). C/EBPβ  (also known as NF-IL6,
LAP, NF-M, AGP/EBP, and CRP2) is a member of the
basic-leucine zipper family of transcription factors [19,
20]. The C/EBPβ  mRNA contains three in-frame me-
thionines which give rise to three different translation
products: p38, p35, and p20-C/EBPβ  [21]. p38 and p35-
C/EBPβ  both contain an N-terminal transactivation do-
main and a C-terminal DNA binding/dimerization do-
main. p20-C/EBPβ  lacks the N-terminal transactivation
domain and therefore acts as a repressor of transcrip-
tion. Our lab has previously shown that p35-C/EBPβ  ac-
tivates an SRE-driven reporter construct while p20-C/
EBPβ  inhibits serum stimulation of the same reporter
[22]. We have also shown that both p35-C/EBPβ  and
p20-C/EBPβ  could interact with SRF in vivo and that the
interaction between SRF and p35-C/EBPβ , but not be-
tween SRF and p20-C/EBPβ , is stimulated by activated
Ras. The target for this Ras stimulation is Thr235 in a
consensus MAPK site in C/EBPβ  [23]. Therefore, C/
EBPβ  is a target of a Ras-dependent signaling pathway
that regulates its interaction with SRF.
Based on the observations that TCF factors as well as
p35-C/EBPβ : (1) interact with SRF (2) transactivate the
SRE and (3) are responsive to Ras-dependent signaling
pathways, we tested the possibility that both TCF and
p35-C/EBPβ  are necessary for maximal induction of the
SRE in response to mitogenic stimulation. In this study,
we show that p35-C/EBPβ  and the TCF family member
Elk-1 synergize in transactivation of SRF dependent
transcription of both a Gal4 dependent reporter and an
SRE-driven reporter construct, but only in response to
mitogenic stimulation by Ras. We further show that Elk-
1 and p35-C/EBPβ  interact in vitro in a glutathione-S-
transferase (GST)-pulldown assay as well as in an in vivo
coimmunoprecipitation assay. The in vivo interaction is
dependent on the presence of activated Ras. Finally, we
show that the C-terminal domain of C/EBPβ  is sufficient
to interact with Elk-1 while the N-terminal A-box of Elk-
1 is necessary to interact with C/EBPβ . These results sug-
gest a cooperative role between the TCF and C/EBPβ
transcription factors in regulation of the c-fos SRE in re-
sponse to Ras-dependent signaling pathways.
Results
Elk-1 and p35-C/EBPβ  synergize in transactivation of a 
GAL4 dependent reporter
Due to the common observations that both Elk-1 and
p35-C/EBPβ  transactivate the SRE, interact with SRF,
and are responsive to Ras-dependent signaling path-
ways, we hypothesized that Elk-1 and p35-C/EBPβ  may
both be necessary for maximal induction of SRF depend-
ent transcription. To begin to test this hypothesis, we
used a GAL4 dependent reporter construct, in which a
CAT reporter gene is driven by five copies of a GAL4
binding site upstream of the adenovirus E1B minimal
promoter (pG5CAT). We constructed a GAL4 DNA bind-
ing domain-SRF fusion protein, as has been described
previously [23]. GAL4-SRF binds to the GAL4 reporter
construct, thereby making transcription of the reporter
gene dependent on the presence of SRF. As shown in Fig.
1, when a GAL4-SRF fusion construct is transfected with
the reporter, there is no increase in CAT activity. The
SRF transactivation domain is weak, as has been shown
previously [24]. When CMV-Elk-1 is cotransfected with
the reporter and GAL4-SRF, there is little increase in
CAT activity in the absence of activated Ras (CMV-
Ras.V12). This result is expected since the transactiva-
tion domain of Elk-1 is activated in response to Ras.
Therefore, when activated Ras is transfected with Elk-1,
GAL4-SRF, and the reporter, the CAT activity increases
to 8-fold over basal levels. We cannot determine if the in-
crease in CAT activity in the presence of Ras also reflects
a stimulation of the interaction of the Elk-1 and SRF pro-
teins.
When CMV-LAP (which encodes p35-C/EBPβ ) is trans-
fected with GAL4-SRF and the reporter construct, we see
a 7-fold increase in CAT activity that is potentiated to 75-
fold when activated Ras is cotransfected. Therefore, C/
EBPβ  results in a much larger increase in transcription
than Elk-1. We have previously shown that Ras does not
activate the transactivation domain of p35-C/EBPβ  [23].
Thus, the increase in transcription in this assay is due to
Ras stimulation of the SRF-p35-C/EBPβ  interaction.
Interestingly, when all three constructs - SRF, Elk-1, and
p35-C/EBPβ -are cotransfected with the reporter con-
struct, there is an average 260-fold increase in CAT activ-BMC Cell Biology (2000) 1:2 http://www.biomedcentral.com/1471-2121/1/2/
ity in the presence of activated Ras. The values of fold
activation varied from as low as 60-fold to as high as 725-
fold over basal levels, and we are unsure of the reason for
this variability. However, regardless of the extent of acti-
vation, in every experiment there was a synergy observed
when both Elk-1 and p35-C/EBPβ  are transfected in the
presence of Ras. There is only a slight increase in CAT ac-
tivity in the absence of Ras. Therefore, Elk-1 and p35-C/
EBPβ  are working synergistically to transactivate the re-
porter construct in the presence of SRF. This synergism
is only observed in response to activation of mitogenic
signaling pathways by Ras.
Elk-1 and p35-C/EBPβ  synergize in transactivation of the 
SRE
Since Elk-1 and p35-C/EBPβ  synergize in transactivation
of SRF-dependent transcription using a GAL4-depend-
ent promoter, we next tested if Elk-1 and p35-C/EBPβ
could also synergize in transactivation of a native SRF
binding site, namely the c-fos SRE. To test this possibili-
ty, NIH 3T3 cells were transiently transfected with a CAT
reporter gene driven by one copy of the wild type SRE
upstream of the Rous sarcoma virus long terminal repeat
minimal promoter. As shown in Fig. 2, when p35-C/
EBPβ  is co-transfected with the reporter construct, there
is a 13-fold increase in CAT activity in the absence of ac-
tivated Ras that is increased to 24-fold when CMV-
Ras.V12 is co-transfected.
When CMV-Elk-1 is co-transfected with the SRE report-
er construct, there is no additional stimulation in trans-
activation in either the absence or presence of Ras
compared to the reporter alone. However, when both
Elk-1 and p35-C/EBPβ  are transfected with the SRE re-
porter construct, there is a synergistic effect in transacti-
vation of the SRE, with a 72-fold increase in CAT activity
over reporter construct alone. As was seen with the Gal4
reporter, this synergism is only observed in the presence
of activated Ras. These data suggest that both Elk-1 and
p35-C/EBPβ  are necessary for maximal Ras-stimulated
transactivation of the SRE.
The TCF family member Elk-1 and C/EBPβ  interact in vitro
We next tested the possibility that there could be a direct
protein-protein interaction between Elk-1 and p35-C/
Figure 1
Elk-1 and p35-C/EBPβ  synergize in SRF dependent transacti-
vation of a GAL4 reporter construct. NIH 3T3 cells were
transfected  with  1  µ g  of  pG5CAT  alone,  with  0.5  µ g  of
pGAL4-SRF, or with  0.5 µ g of pGAL 4-S RF and 0. 5 µ g  of
pCMV-LAP (encoding p35-C/EBPβ ) and/or 0.5 µ g of pCMV-
E l k - 1  a s  i n d i c a t e d ,  i n  t h e  a b s e n c e  a n d  p r e s e n c e  o f  1  µ g
pCMV-Ras.V12. Total DNA in each transfection was adjusted
to 3.5 µ g with pUC19. Cells were serum deprived for 40 h
prior to harvesting. CAT activity was measured as previously
described [33]. Data are the average of 14 determinations,


















































Elk-1 and p35-C/EBPβ  synergize in transactivation of the SRE.
NIH 3T3 cells were transfected with 0.75 µ g of SRE.CAT and
0.75 µ g pCMV-SRF alone or with 0.75 µ g pCMV-LAP or 0.75
µ g pCMV-Elk1 in the absence or presence of 0.75 µ g pCMV-
Ras.V12. Cells were serum deprived for 40 h prior to har-
vesting. CAT activity was measured as previously described
[33]. Data are the average of 4 determinations, and error
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EBPβ  based on the fact that they synergize in transacti-
vation of the SRE. Therefore, we used a GST-pulldown
assay to determine if the proteins could interact in vitro.
p35-C/EBPβ  was expressed as a chimeric GST protein
and immobilized on glutathione-agarose beads. Beads
containing GST-p35-C/EBPβ  or GST alone were incubat-
ed with in vitro-translated Elk-1 labeled with [35S] me-
thionine. As shown in Fig. 3, lane 2, approximately 35-
45% of the input Elk-1 was retained on the GST-p35-C/
EBPβ  beads. A small amount of Elk-1 bound to the beads
containing GST alone (Fig. 3, lane 3) which we have been
unable to eliminate even after blocking with unpro-
grammed translation lysate. However, it is clear that the
binding of Elk-1 is substantially increased when the GST-
p35-C/EBPβ  fusion protein is present on the beads.
These data indicate that Elk-1 and p35-C/EBPβ  are capa-
ble of interacting in vitro.
Elk-1 and p35-C/EBPβ  interact in vivo, but only in the pres-
ence of activated Ras
Since we observed an in vitro interaction between the
Elk-1 and C/EBPβ  proteins, we next tested whether the
proteins could interact in vivo as well. To do this, we
used a co-immunoprecipitation approach. COS-7 cells
were transfected with an expression vector for a 6X his-
tidine tagged construct of p35-C/EBPβ  carrying the φ  10
(T7 tag) epitope sequence either in the presence or ab-
sence of Elk-1. Cell lysates were incubated with T7 tag Ab
agarose beads followed by immunoblotting of the precip-
itated proteins with Elk-1 Ab. As shown in Fig. 4, there is
no Elk-1 protein precipitated with the tagged C/EBPβ
protein when both are transfected (lane 5). However,
since the synergism of Elk-1 and p35-C/EBPβ  is observed
when activated Ras is present, we thought it likely that
the interaction between the two proteins could be Ras-
dependent. Indeed, when activated Ras is co-transfected
along with Elk-1 and histidine-tagged p35-C/EBPβ , the
Elk-1 protein is precipitated with the p35-C/EBPβ  (lane
6). One possible explanation for this result is that Ras in-
creases the amount of p35-C/EBPβ  or Elk-1 protein in
the COS-7 cells, but Western blot analysis showed that
both p35-C/EBPβ  and Elk-1 protein levels are the same
in the absence and presence of Ras (data not shown).
Therefore, p35-C/EBPβ  and Elk-1 interact in vivo, but
only in response to activation of Ras-dependent signal-
ing pathways.
The C-terminal domain of C/EBPβ  is necessary to interact 
with Elk-1 in vitro
Since C/EBPβ  and Elk-1 interact, we next wanted to nar-
row down the domains of the proteins that are required
for their interaction. To determine the domain of C/
EBPβ  that is necessary to interact with Elk-1, a p20-C/
EBPβ -GST fusion protein was constructed. p20-C/EBPβ
Figure 3
Elk-1 binds to GST-p35-C/EBPβ  in vitro. Radiolabeled Elk-1
was  prepared  by  in  vitro t r a n s c r i p t i o n  a n d  t r a n s l a t i o n  o f
CMV-Elk-1  expression  construct  and  then  incubated  with
e q u i v a l e n t  a m o u n t s  o f  G S T  o r  G S T - p 3 5 - C / E B P β  p r o t e i n
immobilized on glutathione-Sepharose. Proteins eluted from
the GST-p35-C/EBPβ  beads (lanes 2) or GST beads (lanes 3)
by  boiling  in  Laemmli  sample  buffer  were  resolved  on  an
SDS-10% polyacrylamide gel and detected by autoradiogra-
phy. Lane 1 contains one-fourth of the amount of the radiola-
beled proteins initially mixed with the beads.
Figure 4
Elk-1  coimmunoprecipitates  with  p35-C/EBPβ ,  but  only  in
the presence of activated Ras. COS-7 cells were transfected
with 10 µ g of pCDNA3.1/His-p35-C/EBPβ  (lanes 1, 2, 5, 6)
and 10 µ g of pCMV-Elk-1 (lanes 3, 4, 5, 6) in the presence
and absence of 2 µ g of pCMV-Ras.V12 as indicated. Cells
were harvested 40 h post-transfection, and whole cell lysates
were incubated with T7tag Ab-agarose beads, followed by
immunoblotting of precipitated proteins with Elk-1 Ab.BMC Cell Biology (2000) 1:2 http://www.biomedcentral.com/1471-2121/1/2/
encodes the 20 kDa form of C/EBPβ , which lacks the N-
terminal transactivation domain of the longer p35-C/
EBPβ  isoform. This isoform, however, shares the C-ter-
minal DNA binding and dimerization domain with p35-
C/EBPβ . As shown in Fig. 5, approximately the same
amount of [35S]-labeled Elk-1 is retained on both the
GST-p20-C/EBPβ  and GST-p35-C/EBPβ  beads (com-
pare lanes 2 and 3). Therefore, deletion of the N-termi-
nus of C/EBPβ  has no effect on its ability to interact with
Elk-1. This data demonstrates that the C-terminal region
of C/EBPβ  is sufficient to mediate interaction with Elk-1
in vitro.
The N-terminal A-box of Elk-1 is sufficient to interact with 
C/EBPβ  in vitro
In order to narrow down the domain of Elk-1 that is nec-
essary to interact with C/EBPβ  in vitro, we made several
Elk-1 deletion mutants (Fig. 6A) and tested these con-
structs in a pulldown assay with GST-p35-C/EBPβ . Elk-
1(1-209) is a C-terminal deletion mutant that lacks the C-
box. Elk-1(1-140) is also a C-terminal deletion, but it
lacks both the B- and C-boxes. Therefore, this mutant
contains neither a transactivation domain nor an SRF
binding domain. Finally, Elk-1(89-428) is a deletion of
the N-terminal A-box. Glutathione agarose beads con-
taining GST-p35-C/EBPβ  or GST alone were incubated
with in vitro-translated Elk-1 mutants labeled with [35S]
methionine. As shown in Fig. 6B, the C-terminal Elk-1
mutants, Elk-1(1-209) and Elk-1(1-140), bound to the
GST-p35-C/EBPβ  beads to the same extent as wild-type
Elk-1 (compare lane 3 of top 3 panels). However, the A-
box deletion mutant, Elk-1(89-428), no longer binds to
the GST-p35-C/EBPβ  (lane 3, bottom panel). Therefore,
this data demonstrates that the A-box of Elk-1 is neces-
sary to interact with C/EBPβ  in vitro.
Discussion
We have shown that the transcription factors Elk-1 and
p35-C/EBPβ  synergize in transactivation of SRF-de-
pendent transcription using both GAL4 and SRE-driven
reporter constructs. Interestingly, this synergy is only
observed in response to mitogenic stimulation by Ras.
We have also demonstrated that the Elk-1 and p35-C/
EBPβ  proteins interact using both in vitro GST-pull-
Figure 5
The C-terminal domain of C/EBPβ  interacts with Elk-1. Radi-
o l a b e l e d  E l k - 1  w a s  p r e p a r e d  b y  in  vitro t r a n s c r i p t i o n  a n d
t r a n s l a t i o n  o f  C M V - E l k - 1  e xp r e s s i o n  c o n s t r u c t  a n d  t h e n
incubated  with  equivalent  amounts  of  GST,  GST-p35-C/
EBPβ , or GST-p20-C/EBPβ  protein immobilized on glutath-
ione-Sepharose. Proteins eluted from the GST-p20-C/EBPβ
beads (lane 2), the GST-p35-C/EBPβ  beads (lane 3) or GST
beads (lanes 4) were resolved on an SDS-10% polyacrylamide
gel and detected by autoradiography. Lane 1 contains one-
half of the amount of the radiolabeled proteins initially mixed
with the beads.
Figure 6
The A-box of Elk-1 is necessary for interaction with p35-C/
EBPβ  in vitro. A) Schematic representation of Elk-1 wild-type
and  deletion  mutants.  B)  Radiolabeled  Elk-1(wt),  Elk-1(1-
209), Elk-1(1-140), and Elk-1(89-428) were prepared by in
vitro transcription and translation of their respective expres-
sion  constructs  (see  Mat.  and  Meth.).  The  proteins  were
incubated with equivalent amounts of GST or GST-p35-C/
EBPβ   protein  immobilized  on  glutathione-Sepharose.  Pro-
teins eluted from the GST beads (lanes 2) or GST-p35-C/
EBPβ  beads (lanes 3) were resolved on an SDS-10% polyacr-
ylamide gel and detected by autoradiography. Lane 1 contains
one-half of the amount of the radiolabeled proteins initially
mixed with the beads.BMC Cell Biology (2000) 1:2 http://www.biomedcentral.com/1471-2121/1/2/
down and in vivo coimmunoprecipitation assays. The in
vivo interaction, however, is dependent on the presence
of activated Ras. Finally, we demonstrate that the in vit-
ro interaction domains of the two proteins are the C-ter-
minal domain of C/EBPβ  and the N-terminal domain of
Elk-1.
These results suggest a new mechanism for transactiva-
tion of the SRE, where a competent transcriptional com-
plex consisting of at least SRF, TCF, and p35-C/EBPβ
participate in transactivation in response to Ras. To this
point, the TCF family members have been thought to be
the main targets of Ras signaling to the SRE, and activa-
tion of TCF by Ras has been shown to result in transacti-
vation of the SRE [16]. However, we show that Ras
activation of TCF alone does not result in maximal SRE
transactivation, but instead, is greatly enhanced in the
presence of p35-C/EBPβ .
SRF and TCF have been shown to form a ternary com-
plex at the SRE in vitro. We as yet have not been able to
observe a ternary complex between SRF and p35-C/
EBPβ  at the SRE in vitro. The mechanisms of SRE trans-
activation described above may help to explain the in vit-
ro results. The C/EBPβ  recognition site in the SRE is a
weak binding site [25]. Upon activation of Ras-depend-
ent signaling pathways, the presence of p35-C/EBPβ  at
the SRE would be stabilized due to its strong protein-
protein interactions not only with SRF, as we have shown
previously [23], but also with Elk-1. It is possible that
p35-C/EBPβ  and SRF are not sufficient to form a ternary
complex with the SRE in vitro, but Elk-1 may also be nec-
essary. In addition, it is likely that p35-C/EBPβ , Elk-1, or
both, may need to be activated by one or more MAPK
family members for a multiprotein complex to form with
SRF at the SRE. Further studies utilizing the information
from the in vivo studies performed here may permit us to
optimize the in vitro conditions necessary to observe
such a multiprotein complex.
We observe a direct interaction between C/EBPβ  and
Elk-1 in a GST pulldown assay. Another ets family mem-
ber, Ets-1, has previously been shown to interact with C/
EBPβ  in vitro [26]. We have not directly tested the ability
of the other TCF famlily members, SAP1 and SAP2/ERP/
NET, to interact with C/EBPβ . We find that the domain
of Elk-1 that interacts with C/EBPβ  is the ets domain,
which is conserved among the other TCF family mem-
bers [16]. We would therefore also expect SAP1 and
SAP2/ERP/NET to interact with C/EBPβ . Interestingly,
the in vivo interaction of Elk-1 and C/EBPβ  is dependent
on activation of Ras-dependent signaling pathways. The
target(s) of the Ras signaling pathway is as yet unknown.
It has been shown that transfection of activated Ras re-
sults in phosphorylation of Thr235 (numbering for hu-
man protein) in the C-terminal domain of C/EBPβ , and
that Thr235 could be phosphorylated by a partially puri-
fied MAPK preparation in vitro [19]. We have also shown
that this same residue is necessary for Ras stimultion of
the interaction between C/EBPβ  and SRF. Therefore, it
will be interesting to determine if this site is also critical
for stimulation of the interaction between C/EBPβ  and
Elk-1. Elk-1 also has several MAPK sites in its C-terminal
domain, and therefore this region could also be a target
for Ras.
We are currently investigating the mechanism of the ob-
served synergy between Elk-1 and p35-C/EBPβ . We have
shown that C/EBPβ  interacts with the A-box of Elk-1,
while SRF has previously been shown to interact with the
B-box [16]. Therefore, C/EBPβ  and SRF interact with
two distinct domains of Elk-1, as well as with each other,
which could allow formation of a complex of the three
transcription factors. This would create an active tran-
scriptional complex at the SRE and result in enhanced
transactivation. It is possible that the p35-C/EBPβ -SRF-
Elk-1 complex could interact more strongly with coacti-
vators and/or the basal transcriptional machinery than
each individual transcription factor. It has been shown
that SRF, TCF, and C/EBPβ  can all interact with compo-
nents of transcriptional machinery such as p300/CBP,
SRC-1, and TFII-I [27,28,29,30]. There is most likely a
large protein complex assembled at the SRE composed of
regulated transcription factors, coactivators, and the ba-
sal transcriptional machinery, resulting in rapid tran-
scription of the c-fos gene in response to mitogenic
stimulation.
Conclusions
This report demonstrates a new model for c-fos SRE ac-
tivation in response to Ras-dependent signaling path-
ways. We show that SRF, Elk-1, and p35-C/EBPβ  are all
necessary for maximal Ras-stimulated transactivation of
the SRE.
Materials and Methods
Cell Culture and Transfections
NIH 3T3 fibroblasts (from the American Type Culture
Collection) and COS-7 cells (kindly provided by Dr. S.
Hann, Vanderbilt University) were grown in Dulbecco's
Modified Eagle Medium (DMEM) with 10% calf serum
(Colorado Serum Company), 0.22% sodium bicarbonate,
4 mM L-glutamine, 25 U of penicillin G sodium per mL,
and 25 mg of streptomycin per mL.
COS-7 cell transfections were performed by the calcium
phosphate (CaPO4) technique [31]. Cells at 60-70% con-BMC Cell Biology (2000) 1:2 http://www.biomedcentral.com/1471-2121/1/2/
fluence were exposed to the CaPO4-DNA precipitate for
8 h. The medium was removed and replaced with com-
plete medium for 36 h before harvesting. NIH 3T3 trans-
fections were performed using NovaFector (Venn Nova)
or Trans-IT LT1 (PanVera) as described by the manufac-
turers.
For NovaFector transfections, a 6:1 ratio of NovaFec-
tor:DNA was used for each transfection. Cells at 60-70%
confluence were exposed to the NovaFector:DNA com-
plex for 6-7 h in serum and antibiotic free medium. After
the incubation, an equal volume of DMEM containing
20% calf serum was added for 24 h, bringing the final
concentration of calf serum to 10%. Cells were then se-
rum deprived for 36-40 h in DMEM supplemented as
above except containing 0.5% calf serum before harvest-
ing. For TransIT-LT1 transfections, a 6:1 ratio of Tran-
sIT-LT1:DNA was used in each transfection. Cells at 60-
70% confluence were exposed to the TransIT-LT1:DNA
complex for 8 h in complete medium plus freshly added
30 mg/mL polymyxin B antibiotic [32]. The medium was
then removed and replaced with complete medium for
24 h. Cells were then serum deprived in DMEM contain-
ing 0.5% calf serum for 36-40 h before harvesting. Cell
extracts were prepared and chloramphenicol acetyl
transferase (CAT) assays were performed on extracts
containing equivalent cell protein as previously de-
scribed [33]. An internal control plasmid to measure
transfection efficiency could not be used because C/
EBPβ  regulates transcrption from the control plasmid,
and thus makes the internal control invalid. Therefore,
the transfections were repeated multiple times to control
for variability in transfection efficiency.
Plasmids
The pGAL4 and pG5CAT plasmids were obtained from
the Mammalian MATCHMAKER Two-Hybrid Assay Kit
(CLONTECH). pGAL4-SRF was constructed as previ-
ously described [23]. The SRE-CAT reporter gene was
constructed as previously described [22]. pGST-p35-C/
EBPβ  was constructed by inserting the 1,739 bp EcoRI
fragment from pRSETB-EFII [34] into EcoRI cut pGEX-
4T-1 (Amersham-Pharmacia). pGST-p20-C/EBPβ  was
constructed by inserting the 581 bp BamHI/EcoRI frag-
ment from pRsetA-LIP [34] into similarly digested
pGEX4T-1. pcDNA3/Elk-1(1-209) and pcDNA3/Elk-1(1-
140) were constructed by using the Erase-A-Base system
(Promega) with pcDNA3/Elk-1 (gift of J. Schwartz, Univ.
of Michigan) as described by the manufacturer.
pcDNA3.1/His-p35-C/EBPβ  was constructed by insert-
ing an 1,739 bp EcoRI fragment from pRSETB-EFII into
an EcoRI cut pcDNA3.1/HisC vector (Invitrogen). CMV-
LAP was a gift of U. Schibler (Univ. of Geneva, Geneva,
Switzerland) and CMV-Ras.V12 was a gift of E. Ruley
(Vanderbilt Univ.).
Analysis of ELK-1 and C/EBPβ  interaction in vitro
GST-p35-C/EBPβ , GST-p20-C/EBPβ , or GST alone was
produced in BL21 E. Coli by 80 mM isopropyl-β -D-thi-
ogalactopyranoside (IPTG) induction overnight at 37° C.
Cells were harvested by centrifugation and washed once
with phosphate-buffered saline (PBS) containing the fol-
lowing protease inhibitors: 2 mg/ml aprotinin, 2 mg/ml
leupeptin, 2 mM phenylmethylsulfonyl fluoride (PMSF),
and 0.2 mM pepstatin. The bacteria were lysed by soni-
cation at 4oC in PBS containing the protease inhibitors
described above. Triton X-100 was added to a final con-
centration of 0.1%, followed by gentle mixing for 30 min
at 4° C. The lysate was clarified at 12,000 ×  g for 10 min
at 4° C. The supernatant was gently mixed with glutath-
ione-sepharose beads (Amersham-Pharmacia) at 4° C for
30 min. Beads containing GST proteins were collected by
low speed centrifugation, followed by three successive
washes with PBS containing 0.1% Triton X-100 and the
protease inhibitors described above.
The ELK-1, ELK-1(1-209), ELK-1(1-140), and ELK-1(89-
428) proteins were transcribed and translated in vitro
using the TNT T7 coupled reticulocyte lysate system
(Promega) according to the manufacture's instructions.
Translated proteins were radiolabeled with the
EXPRE35S35S protein labeling mix (Dupont NEN). The
GST-pulldown assay was done as previously described
[22].
Co-Immunoprecipitation
COS-7 cells were harvested in PBS containing 0.1 mM so-
dium vanadate and collected by low speed centrifuga-
tion. Cells were resuspended in lysis buffer (10 mM Tris
(pH 7.5), 1 mM EDTA, 50 mM NaCl, 0.25% Nonidet P-
40, 1 mM PMSF, 1 mg of aprotinin/mL, 0.1 mM sodium
vanadate, 10 mM sodium molybdate, and 10 mM β -glyc-
erol phosphate) and lysed by sonication with a microtip
on setting 2 and 20% duty cycle for 10 s. After clarifica-
tion by centrifugation at 12,000 ×  g for 10 min, the cell
extract was incubated with T7 tag antibody (Ab)-agarose
beads (Novagen) for 2 h. The beads were collected by low
speed centrifugation and washed 3 times with lysis buff-
er. All steps were performed at 4° C. After washing, the
beads were boiled for 5 min in Laemmli sample buffer.
Immunoblots
The samples from the coimmunoprecipitations de-
scribed above were analyzed by electrophoresis on an
SDS-12% polyacrylamide gel for 3 h at 160 V. The gel was
equilibrated in transfer buffer (33 mM Tris base, 192 mMBMC Cell Biology (2000) 1:2 http://www.biomedcentral.com/1471-2121/1/2/
glycine, 20% methanol) for 15 min before transfer of pro-
teins to Immobilon-P membrane (Millipore Corp.). After
transfer, an immunoblot was performed as described
previously [22]. A 1:2000 dilution of anti-Elk-1 Ab (San-
ta Cruz Biotechnology) and a 1:5000 dilution of goat
anti-rabbit secondary Ab (Roche Molecular Biochemi-
cals) were used. The secondary Ab was detected using
SuperSignal Chemiluminescent Substrate (Pierce).
Abbreviations
aa, amino acid; Ab, antibody; bp, base pair; CaPO4, cal-
cium phosphate; C/EBPβ , CCAAT-enhancer binding
protein-beta; CAT, chloramphenicol acetyl transferase;
DMEM, Dulbecco's Modified Eagle Medium; GST, glu-
tathione-S-transferase; MAPK, mitogen activated pro-
tein kinase; PBS, phosphate buffered saline; PMSF,
phenylmethylsulfonyl fluoride; SRE, serum response el-
ement; SRF, serum response factor; TCF, ternary com-
plex factor.
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